1. Renal cortical cyclooxygenase 2 expression is differentially regulated by angiotensin II AT(1) and AT(2) receptors. Zhang MZ, Yao B, Cheng HF, Wang SW, Inagami T, Harris RC (2006) Proc Natl Acad Sci U S A 103(43): 16045-50
    › Primary publication · 17043228 (PubMed) · PMC1635124 (PubMed Central)
  2. Potential side effects of renin inhibitors--mechanisms based on comparison with other renin-angiotensin blockers. Cheng H, Harris RC (2006) Expert Opin Drug Saf 5(5): 631-41
    › Primary publication · 16907653 (PubMed)
  3. Nitric oxide stimulates cyclooxygenase-2 in cultured cTAL cells through a p38-dependent pathway. Cheng HF, Zhang MZ, Harris RC (2006) Am J Physiol Renal Physiol 290(6): F1391-7
    › Primary publication · 16380459 (PubMed)
  4. Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice. Zhao HJ, Wang S, Cheng H, Zhang MZ, Takahashi T, Fogo AB, Breyer MD, Harris RC (2006) J Am Soc Nephrol 17(10): 2664-9
    › Primary publication · 16971655 (PubMed) · PMC4618687 (PubMed Central)
  5. COX-2 and the kidney. Harris RC (2006) J Cardiovasc Pharmacol : S37-42
    › Primary publication · 16785827 (PubMed)
  6. Characterization of diabetic nephropathy in a transgenic model of hypoinsulinemic diabetes. Kanetsuna Y, Hirano K, Nagata M, Gannon MA, Takahashi K, Harris RC, Breyer MD, Takahashi T (2006) Am J Physiol Renal Physiol 291(6): F1315-22
    › Primary publication · 16705146 (PubMed)
  7. Role of mammalian target of rapamycin signaling in compensatory renal hypertrophy. Chen JK, Chen J, Neilson EG, Harris RC (2005) J Am Soc Nephrol 16(5): 1384-91
    › Primary publication · 15788477 (PubMed)
  8. Renal effects of non-steroidal anti-inflammatory drugs and selective cyclooxygenase-2 inhibitors. Cheng HF, Harris RC (2005) Curr Pharm Des 11(14): 1795-804
    › Primary publication · 15892676 (PubMed)
  9. Mouse models of diabetic nephropathy. Breyer MD, Böttinger E, Brosius FC, Coffman TM, Harris RC, Heilig CW, Sharma K, AMDCC (2005) J Am Soc Nephrol 16(1): 27-45
    › Primary publication · 15563560 (PubMed)
  10. Lithium treatment inhibits renal GSK-3 activity and promotes cyclooxygenase 2-dependent polyuria. Rao R, Zhang MZ, Zhao M, Cai H, Harris RC, Breyer MD, Hao CM (2005) Am J Physiol Renal Physiol 288(4): F642-9
    › Primary publication · 15585669 (PubMed)